[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100479821":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":10,"locations":16,"responsibleParty":28,"collaborators":10,"id":30,"slug":31,"hasResults":32,"nctId":33,"briefTitle":34,"officialTitle":35,"acronym":10,"eligibilityCriteria":36,"healthyVolunteers":32,"sex":37,"minAge":38,"maxAge":10,"enrollmentInfo":39,"targetDuration":42,"studyType":43,"phases":10,"briefSummary":44,"conditions":45,"keywords":10,"overallStatus":47,"whyStopped":10,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":55,"locationsCount":56},{"fullName":5,"class":6},"Sanofi","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Patients with severe refractory atopic dermatitis",null,"Patients eligible for Dupixent therapy of AD",[13],{"name":14,"affiliation":5,"role":15},"Clinical Sciences & Operations","STUDY_DIRECTOR",[17],{"facility":18,"status":10,"city":19,"state":10,"zip":20,"country":21,"countryCode":10,"cosmosGeoPoint":22,"geoPoint":27,"contacts":10},"Investigational Site: Bulovka University Hospital","Prague","180 81","Czechia",{"type":23,"coordinates":24},"Point",[25,26],14.42076,50.08804,{"lat":26,"lon":25},{"type":29,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100479821","a-study-to-evaluate-the-quality-of-life-of-male-and-female-adult-patients-with-severe-refractory-atopic-dermatitis-treated-with-dupilumab-in-czech-republic-100479821",false,"NCT05527964","A Study to Evaluate the Quality of Life of Male and Female Adult Patients With Severe Refractory Atopic Dermatitis Treated With Dupilumab in Czech Republic","The Influence of Specific Targeted Therapy on Subject and Family Quality of Life, Anxiety, Depression and Sleep Quality in Patients With Severe Refractory Atopic Dermatitis in the Czech Republic","Inclusion Criteria:\n\n* Patient eligible for Dupixent therapy of AD according to the current SPC and reimbursement criteria given by the SUKL\n* Signed informed consent\n* 18 years and older (study questionnaires are validated for this age group). Patient is able to follow the prescribed regimen, routine follow-up visits and to fill the questionnaires\n\nExclusion Criteria:\n\n\\- Patient not eligible for Dupixent therapy of AD according to the current SPC and reimbursement criteria given by the SUKL.\n\nThe above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.","ALL","18 Years",{"count":40,"type":41},146,"ACTUAL","28 Weeks","OBSERVATIONAL","Assessment of the relationship between treatment response (EASI75) and change in quality of life (EQ-5D) by week 24.\n\nDescription of the:\n\n* Change in disease activity after 16 and 24 weeks\n* Change in subject and family quality of life after 16 and 24 weeks\n* Change in sleep quality after 16 and 24 weeks\n* Change in anxiety after 16 and 24 weeks\n* Change in depression after 16 and 24 weeks\n* Safety and tolerability",[46],"Atopic Dermatitis","COMPLETED","2025-08-14",{"date":50,"type":41},"2025-08-15",{"date":52,"type":41},"2022-12-30",{"date":54,"type":41},"2025-06-16",{"name":5,"class":6},1]